Fig. 6: In vivo activity of BZT against Mtb and STm. | npj Antimicrobials and Resistance

Fig. 6: In vivo activity of BZT against Mtb and STm.

From: The Parkinson’s drug benztropine possesses histamine receptor 1-dependent host-directed antimicrobial activity against Mycobacterium tuberculosis

Fig. 6

a Oral treatment with 10 mg/kg and 20 mg/kg BZT reduced Mtb load in the lungs of Mtb-infected mice. Rifampin (RIF) at 10 mg/kg and 25 mg/kg, served as a positive control. BZT did not reduce Mtb levels in mouse; b livers; c spleens. BZT (5 mg/kg, subcutaneous) reduced; d abscess size; and e bacterial recovery from abscesses in a STm high-density abscess model. f BZT reduced clinical signs of morbidity resulting from high-density subcutaneous infection with STm. Data represent the mean ± SEM of two or three independent experiments containing 2–3 biological replicates each (N = 5–6). Statistical significance was determined using the Mann–Whitney U-test; ****p < 0.0001, ***p < 0.001, **p < 0.005, ns non-significant, NT non-treated controls.

Back to article page